ArticleInternational journal of nanomedicine2025
Multimodal Imaging-Guided Tumor Microenvironment-Responsive Nanoplatform for Synergistic Therapy of Pancreatic Cancer.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MRI-enabled ferroptosis self-amplifying nanoplatform synergizes with photothermal therapy to enhance chemotherapeutic efficacy against pancreatic cancer.Materials today. Bio · 2026Article
- EVs from Stem Cells Improve Mitochondrial Dysfunction in Neuronal Disorders.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Chemotherapy remains an effective treatment for pancreatic cancer. However, the limitations of single-modal therapies and the absence of imaging-based monitoring during treatment pose challenges for real-time optimization of drug delivery, resulting in suboptimal therapeutic outcomes. Methods: This study aims to design and develop a novel nanoparticle drug delivery system, HMP-ICG&DOX, which incorporates indocyanine green (ICG) as an FDA-approved near-infrared photothermal agent and doxorubicin (DOX) as a commonly used chemotherapeutic drug. The modification with NH Results: Experimental results demonstrate that HMP-ICG&DOX nanoparticles possess excellent biocompatibility, antitumor activity, controlled drug release, and multimodal imaging tracking abilities. Conclusion: In conclusion, the HMP-ICG&DOX nanoparticles designed in this study offer promising applications in the diagnosis and treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.